Johnson & Johnson reported a record-breaking quarter exceeding $15 billion in pharmaceutical sales, despite significant declines in its blockbuster drug Stelara due to generic competition. The company’s innovative medicines division, led by strong oncology sales—including Darzalex and Carvykti—and immunology gains from Tremfya, drove growth. Med-tech segments also reported higher-than-expected growth, with cardiology showing a 22.3% increase. CEO Joaquin Duato reiterated ambitions to become the top oncology company by 2030, emphasizing robust performance across multiple categories. J&J raised its income guidance and forecasts moderated impacts from recent tariff threats in the medical device sector.